1 Min Read
* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.